Seven Eight Capital, LP Editas Medicine, Inc. Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$6.25 - $11.11 $914,656 - $1.63 Million	146,345 New	146,345 $1.48 Million
Q3 2022 Nov 10, 2022	BUY	$12.16 - $19.42 $279,230 - $445,941	22,963 New	22,963 $281,000
Q1 2022 May 11, 2022	SELL	$14.08 - $27.63 $147,445 - $289,341	-10,472 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $278,031 - $424,849	10,472 New	10,472 $278,000
Q1 2020 May 14, 2020	SELL	$14.88 - $32.78 $927,024 - $2.04 Million	-62,300 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$19.49 - $32.63 $1.21 Million - $2.03 Million	62,300 New	62,300 $1.85 Million

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.